Publication des lignes directrices du traitement des Néoplasies Myéloprolifératives
Les lignes directrices du traitement des Néoplasies Myéloprolifératives sont maintenant disponible sur notre site web. Visitez la section Guides thérapeutiques NMP…
Archive de Michael Harnois
La version 2015 des lignes directrices du traitement de la LMC sont maintenant en ligne dans la section Guides Thérapeutiques
ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 6, 2015– ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), today announced that Health Canada has approved the use of…
World CML Day 9/22: Today, Together
On one day, 22 September 2015, one community across the globe stands together to raise awareness about one life changing…
Combattre les cancers rares | Métro
«Les maladies rares ont moins de chance d’être reconnues par les professionnels de la santé, c’est une difficulté inhérente à…
Blueprint for the Next Generation of Chronic Myeloid Leukemia Treatment
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene…
ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe Completion Expected in October 2014
CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Jul. 14, 2014– ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee…